Oklahoma Medical Research Foundation
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1946-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.omrf.org
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT04726553
- Locations
- 🇺🇸
Yale University Medical Center, New Haven, Connecticut, United States
🇺🇸New York University Medical Center, New York, New York, United States
🇺🇸Columbia Unversity Medical Center, New York, New York, United States
Antecedent Metabolic Health and Metformin Aging Study
- Conditions
- Chronic DiseaseInsulin ResistanceInsulin SensitivityMitochondriaAging
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 101
- Registration Number
- NCT04264897
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources, Oklahoma City, Oklahoma, United States
🇺🇸University of Wisconsin-Madison, Madison, Wisconsin, United States
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE
- Conditions
- Systemic Lupus Erythematosus Arthritis
- Interventions
- Drug: Placebos
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 9
- Registration Number
- NCT03355482
- Locations
- 🇺🇸
Access Health, Las Vegas, Nevada, United States
Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: belimumab
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT02270970
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: PlaceboBiological: Abatacept
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 66
- Registration Number
- NCT02270957
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: extended release dipyridamole 200mg/aspirin 25mg
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 18
- Registration Number
- NCT01781611
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Safety of Zostavax Vaccination in Rheumatoid Arthritis
- Conditions
- Rheumatoid ArthritisVaricella Zoster
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT01506661
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Zostavax in Systemic Lupus Erythematosus
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT01474720
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT01213017
- Locations
- 🇺🇸
Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States
🇺🇸Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Group A SLE prospective studyOther: Blood drawing only Group COther: Group B SLE one blood donation
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 158
- Registration Number
- NCT00987831
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
🇺🇸Pfizer Inc, Collegeville, Pennsylvania, United States